Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series

Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of advanced ALK-rearrangement positive non-small-cell lung cancer (NSCLC). Many tolerable adverse events were reported with the use of Alectinib; nevertheless, hemolytic anemia was not mentioned in the...

全面介紹

書目詳細資料
發表在:Current Oncology
Main Authors: Rola El Sayed, Mustapha Tehfe, Normand Blais
格式: Article
語言:英语
出版: MDPI AG 2022-12-01
主題:
在線閱讀:https://www.mdpi.com/1718-7729/30/1/41

相似書籍